(-)-Epigallocatechin-3-gallate ameliorates learning and memory deficits by adjusting the balance of TrkA/p75NTR signaling in APP/PS1 transgenic mice

Created: 2021-08-07T02:58:49-05:00

Return to the Index

This card pertains to a resource available on the internet.

(-)-Epigallocatechin-3-gallate (EGCG)

In this study, we found that EGCG treatment (2 mg·kg(-1)·day(-1)) dramatically ameliorated the cognitive impairments, reduced the overexpressions of Aβ(1-40) and amyloid precursor protein (APP), and inhibited the neuronal apoptosis in the APP/PS1 mice.